文献速递胸部肿瘤

度伐利尤单抗在晚期非小细胞肺癌患者中的临床活性、耐受性及长期随访

Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC.
PubMed 文献 · J Thorac Oncol · 2019-06-20

这项I/II期研究纳入304例IIIB-IV期非小细胞肺癌患者,接受度伐利尤单抗10 mg/kg每2周治疗,主要终点为安全性和抗肿瘤活性。PD-L1≥25%组确认客观缓解率为21.8%,PD-L1<25%组为6.4%;中位总生存期12.4个月,中位无进展生存期1.7个月。

要点

  • PD-L1≥25%组确认客观缓解率21.8%,PD-L1<25%组为6.4%。
  • 中位总生存期12.4个月,中位无进展生存期1.7个月。
  • 治疗相关不良事件发生率57.2%,3/4级10.2%,导致停药5.6%。

核心结论

  • 度伐利尤单抗在多数经治的非小细胞肺癌人群中不论组织学类型均具有临床活性,安全性可控。
  • 肿瘤PD-L1表达较高的患者中缓解率和生存似乎增强。

研究设计与样本

  • I/II期试验(Study 1108;NCT01693562)的非小细胞肺癌队列,纳入IIIB-IV期鳞癌或非鳞癌患者304例。
  • 患者接受度伐利尤单抗10 mg/kg每2周,持续12个月或直至确认疾病进展或不可接受毒性。
  • 主要目标为安全性和抗肿瘤活性;肿瘤PD-L1表达采用VENTANA SP263检测;疗效由盲法独立中心审查按RECIST v1.1评估。
  • 不良事件按美国国家癌症研究所常见不良事件术语标准v4.03分级。

主要发现

  • 304例患者中79.0%既往接受过治疗。
  • 确认客观缓解率:PD-L1≥25%组为21.8%,PD-L1<25%组为6.4%;一线治疗组为25.9%,经治组为12.7%;鳞癌组为14.0%,非鳞癌组为16.7%。
  • 中位总生存期为12.4个月,中位无进展生存期为1.7个月。
  • PD-L1≥25%组 vs PD-L1<25%组:中位总生存期16.4个月 vs 7.6个月,中位无进展生存期2.6个月 vs 1.4个月。
  • 治疗相关不良事件发生率为57.2%,3/4级为10.2%,导致停药为5.6%;1例患者(0.3%)死于治疗相关肺炎(基础肺膜炎)。

关键数值与推荐

  • PD-L1表达以≥25%与<25%分层评估疗效。
  • 疗效评估采用RECIST v1.1,由盲法独立中心审查判定确认缓解。
  • 不良反应分级采用NCI CTCAE v4.03。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Durvalumab is a selective, high-affinity human immunoglobulin G1 monoclonal antibody that blocks programmed cell death ligand 1 (PD-L1) binding to programmed death 1. Here we report safety and clinical activity in the NSCLC cohort of a phase I/II trial that included multiple tumor types (Study 1108; NCT01693562). METHODS: Patients with stage IIIB-IV NSCLC (squamous or nonsquamous) received durvalumab 10 mg/kg every 2 weeks for 12 months or until confirmed progressive disease or unacceptable toxicity. Primary objectives were safety and antitumor activity. Tumoral PD-L1 expression was assessed using the VENTANA SP263 Assay. Responses were assessed by blinded independent central review (Response Evaluation Criteria in Solid Tumors v1.1). Adverse events were graded according to National Cancer Institute's Common Terminology Criteria for Adverse Events (v4.03). RESULTS: Of 304 patients, 79.0% were previously treated. Confirmed objective response rate was 21.8% in patients with greater than or equal to 25% PD-L1 expression and 6.4% in those with less than 25%; 25.9% in first-line patients and 12.7% in previously treated patients; and 14.0% in squamous and 16.7% in nonsquamous disease. Median overall survival was 12.4 months and median progression-free survival was 1.7 months; both were numerically longer in the PD-L1 greater than or equal to 25% group than in the PD-L1 less than 25% group (overall survival 16.4 versus 7.6 months, respectively; progression-free survival 2.6 versus 1.4 months, respectively). Treatment-related adverse events occurred in 57.2%, were grade 3/4 in 10.2%, and led to discontinuation in 5.6%. One patient (0.3%) died of treatment-related pneumonia with underlying pneumonitis. CONCLUSIONS: Durvalumab was clinically active irrespective of histology in this mostly pretreated population, with a manageable safety profile. Response rates and survival appeared to be enhanced in patients with greater tumoral PD-L1 expression.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Antonia SJ, Balmanoukian A, Brahmer J, et al. Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. J Thorac Oncol. 2019. PMID: 31228626. doi:10.1016/j.jtho.2019.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。